Research programme: type 2 diabetes therapeutics - Boehringer/Depomed
Latest Information Update: 29 Mar 2012
At a glance
- Originator Boehringer Ingelheim; Depomed
- Mechanism of Action Glucose modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 29 Mar 2012 Preclinical development is ongoing in Germany